Clinical trials: Glucose Response
Diabetes Mellitus, Type 1
Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2
DEFEND-2 is a Phase 3 confirmatory study for the Phase 3 DEFEND-1 study. The study objective is to find out if an 8-day series of otelixizumab infusions leads to greater improvement in insulin secretion as compared with placebo.
- Trial name
- DEFEND-2 (NCT01123083)
- Testing
- Otelixizumab
- Where
- Italy
- Volunteers
- 179 people
- Sponsor
- GlaxoSmithKline
Glucose Intolerance
Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)
This study is being done to evaluate the safety, efficacy, and dose level of sitagliptin (MK-0431/ONO-5435) used once daily (qd) in Japanese participants with impaired glucose tolerance who have inadequate glycemic control using…
- Trial name
- NCT01405911
- Testing
- Sitagliptin 25 mg, Sitagliptin 50 mg
- Volunteers
- 242 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM
Primary objective: The primary objective of this study is to define the dose response of Glymera as measured as the change from baseline in hemoglobin A1c (HbA1c) following 20 weeks of once-weekly dosing.
- Trial name
- NCT01658501
- Testing
- 50 mg PB1023, 70 mg PB1023, 100 mg PB1023
- Where
- 93 sites in United States
- Volunteers
- 593 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes
This mechanistic study is designed to investigate the effect of vildagliptin on the sensitivity of the a-cell to glucose under hypoglycemic conditions in patients with type 2 diabetes (T2DM).
- Trial name
- NCT00390520
- Testing
- Vildagliptin
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- Novartis
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to evaluate the blood glucose-lowering effect of NN5401 (insulin degludec/insulin aspart (IDegAsp)) in subjects with type 2 diabetes.
- Trial name
- NCT01134224
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart 30
- Where
- Germany
- Volunteers
- 39 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes
This trial was conducted in Europe. The aim of this clinical trial was to evaluate the effect on the blood glucose-lowering effect of NN1250 (insulin degludec) in subjects with type 1 diabetes.
- Trial name
- NCT01114542
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus
This will be a randomized, open-label, active-controlled, 6-period crossover study. Target population will be subjects with Type 2 Diabetes Mellitus (T2DM)
- Trial name
- T2DM (NCT04100473)
- Testing
- Inhaled Human Insulin, Insulin Lispro (Humalog U-100)
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Dance Biopharm Inc.
Diabetes, Diabetes Mellitus, Type 2
A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes
This trial was conducted in Europe. The aim of this clinical trial was to evaluate the blood glucose-lowering effect of NN1250 (insulin degludec/insulin 454) in subjects with type 2 diabetes.
- Trial name
- NCT01154881
- Testing
- insulin degludec
- Where
- Germany
- Volunteers
- 49 people
- Sponsor
- Novo Nordisk A/S
Blood Glucose
Blood Glucose Response After Oral Intake of Lactulose in Healthy Volunteers
Prospective, open, mono-center, randomized, two part study with 4-way cross-over design in each study part. The objective of the study is to investigate blood glucose levels after oral intake of defined amounts of lactulose.
- Trial name
- NCT02968498
- Testing
- Lactulose crystals 10 g, Lactulose crystals 20 g, Lactulose liquid 10 g
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Fresenius Kabi
Hyperglycemia
Efficacy of a Brown Seaweed Extract Rich in Polyphenols on Glycemic Response to Sucrose in Human
The primary endpoint of this trial will be to evaluate if a single administration in human of a lemon ice tea containing 500 mg of a polyphenol-rich algal powder is able to reduce postprandial glycemia and insulinemia.
- Trial name
- NCT01384110
- Testing
- Reduction of glycemic index of ingested foods
- Where
- Canada
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- innoVactiv Inc.
Diabetes Mellitus, Type 2
Glycemic Response in Persons with Type 2 Diabetes
This will be a randomized crossover design with nutrition supplement interventions.
- Trial name
- NCT04413357
- Testing
- Balanced Nutritional Drink, Diabetes Specific, Balanced Nutritional Drink (DMA), Diabetes Specific, Balanced Nutritional Drink DMB
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Société des Produits Nestlé (SPN)
Diabetes Mellitus, Type 2
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of CNTO 3649 following a single dose in healthy adults and following multiple doses in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT00882726
- Testing
- CNTO 3649 IV (Healthy participants), CNTO 3649 SC (Healthy participants), CNTO 3649 SC (Diabetic patients)
- Where
- 3 sites in United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Diabetic Foot Ulcers
Safety Study of Topical Human FGF-1 for Wound Healing
The purpose of the study is to see if FGF-1 is safe when applied topically to the surface of a wound.
- Trial name
- NCT00916292
- Testing
- FGF-1 141
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Phage Pharmaceuticals, Inc.
Type 2 Diabetes
Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes
The purpose of this study is to assess the efficacy response of rivoglitazone HCl on the change in HbA1c after 12 weeks of treatment in patients with type 2 diabetes.
- Trial name
- NCT00575471
- Testing
- Rivoglitazone HCl
- Where
- 3 sites in Japan
- Volunteers
- 250 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Glucose, High Blood, Glucose, Low Blood
Post-prandial Glycemic Response to Fiber in Healthy Adults
This randomized, double-blind, comparator controlled trial evaluated the blood glucose and insulin responses in healthy adults, after consuming a high fiber or low fiber muffin top.
- Conditions
- Glucose, High Blood, Glucose, Low Blood, Meals
- Trial name
- NCT03252704
- Testing
- resistant starch (high fiber muffin top), control (low fiber muffin top)
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Ingredion Incorporated
Type 2 Diabetes Mellitus
18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes
Designed to evaluate dose response of force-titrated prandial administration of TI as compared to placebo (TP) in subjects with Type 2 diabetes who were suboptimally controlled
- Trial name
- NCT00511732
- Testing
- Technosphere Insulin
- Volunteers
- 227 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus Type 1
A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes
The addition of BioChaperone to insulin lispro may accelerate the onset and shorten the duration of action of insulin lispro due to facilitation of the absorption of the insulin after subcutaneous injection.
- Trial name
- NCT02146651
- Testing
- BioChaperone insulin lispro 0.2U/Kg, BioChaperone insulin lispro 0.1U/Kg, BioChaperone insulin lispro 0.4U/Kg
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Adocia
Diabetes Mellitus, Type 1
A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients
The goal of this study is to determine if treatment with TCD601 improves beta-cell function in adults recently diagnosed with type 1 diabetes compared to placebo.
- Trial name
- STRIDE (NCT06025110)
- Testing
- TCD601
- Where
- 26 sites in Belgium, Italy and 3 more
- Volunteers
- 9 people
- Sponsor
- ITB-Med LLC
Type 1 Diabetes Mellitus
Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System
The purpose of this study is to assess the efficacy of the Low Glucose Suspend (LGS) feature in reducing hypoglycemia with the MiniMed Paradigm® X54 System with hypoglycemic induction from exercise.
- Trial name
- NCT01148862
- Testing
- The MiniMed Paradigm® X54 System
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes
To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension
To evaluate the hormonal response to low blood sugar after a single oral dose of AZD1656 suspension.
- Trial name
- NCT00790153
- Testing
- Insulin, AZD1656
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca